BGLP40 - BGLP40 is a completely synthetic MUC1-based liposomal glycolipopeptide cancer vaccine for potential use in several cancer indications. The antigen incorporated in BGLP40 combines carbohydrate and peptide determinates in a multi-epitopic vaccine that evokes both cell- and antibody-mediated immune responses against major cancer-associated targets expressed on adenocarcinomas. The vaccine also includes the fully synthetic PET-lipid A adjuvant which is proprietary to Oncothyreon.
Oncothyreon currently intends to substantially complete the pre-clinical development of BGLP40 in 2010, with the goal of initiating clinical development in 2011. Merck KGaA has a right of first negotiation with respect to the development or marketing of BGLP40.
PX-866 - PX-866 is a small molecule inhibitor of the PI-3-kinase/PTEN/AKT pathway, an important survival signaling pathway that is activated in many types of human cancer. Oncothyreon is currently conducting a Phase 1 trial of PX-866 in patients with advanced metastatic cancer. The trial includes both an intermittent and a continuous dosing arm. The maximally-tolerated dose has been identified in the intermittent dosing arm, and patient entry has begun in the continuous dosing arm of the study.
Based upon the results seen in this trial to date, including the preliminary data presented at the American Society of Oncology meeting earlier this year, Oncothyreon has made the decision to move PX-866 into Phase 2 clinical development in the first half of 2010. The Phase 2 development program is currently expected to include two or more trials of PX-866 in combination with chemotherapy or other targeted agents and as a single agent.
PX-478 - PX-478 is a novel small molecule compound that inhibits the activity of hypoxia inducible factor (HIF)-1 alpha, a component of the transcription factor HIF-1 that controls the expression of a number of genes important for growth and surviva
|SOURCE Oncothyreon Inc.|
Copyright©2009 PR Newswire.
All rights reserved